We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo






  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 70

Competition concerns in the German healthcare market

  • Dierks & Bohle Attorneys at Law
  • -
  • Germany
  • -
  • May 15 2013

Following a 10-year absence, competition law is finally establishing itself in the German healthcare market and is paving the way for equal

Germany seeks stricter nanomaterial reporting rules under REACH

  • Shook Hardy & Bacon LLP
  • -
  • European Union, Germany
  • -
  • May 10 2013

German safety regulators have apparently sought a major nanotechnologyrelated revision of the European Union's Registration, Evaluation

Dispelling the Myriad gene patent harmonization myth

  • Foley & Lardner LLP
  • -
  • Australia, Canada, European Union, France, Germany, Japan, USA
  • -
  • April 30 2013

In the wake of the Supreme Court oral arguments in the Myriad "gene patent" case, most commentators are predicting that the Court will uphold the

Federal Court of Justice: extended advertising options for the pharmaceutical industry

  • Baker & McKenzie
  • -
  • Germany
  • -
  • March 26 2013

In its judgment dated 2 February 2013 (I ZR 6211) the German Federal Court of Justice (BundesgerichtshofBGH) extended the advertising options for

Amendments to German Drug Advertising Act

  • Baker & McKenzie
  • -
  • Germany
  • -
  • March 26 2013

Amendments have been made to the German Drug Advertising Act (HeilmittelwerbegesetzHWG) (Act) by the so-called "Second Act Amending Drug Law and

Stricter legislation on corruption in healthcare looming

  • Squire Sanders
  • -
  • Germany
  • -
  • March 22 2013

For years there has been a public debate in Germany about corruption in the healthcare sector - not least because of the huge economical detriments

FSC decides on patentability of neural progenitor cells II (Brustle)

  • Bird & Bird
  • -
  • Germany
  • -
  • February 25 2013

Recently, the German Federal Supreme Court decided on a nullity action on the patentability of progenitor cells extracted from human embryonic stem

Healthcare compliance: stricter anti-corruption rules on the horizon

  • CMS Hasche Sigle
  • -
  • Germany
  • -
  • February 11 2013

Is a practice-based doctor risking criminal punishment if he or she accepts money from a pharmaceutical company for prescribing drugs? Does the same

German Supreme Court finally finds patent on embryonic stem cell technology valid under reasonable terms while the position of the EPO is still open

  • Prüfer & Partner GbR
  • -
  • European Union, Germany
  • -
  • February 1 2013

Following the preliminary ruling of the Court of Justice of the European Union (CJEU; case C-3410), the long awaited final decision of the German

German court re-enforces incentives ban against manufacturer: no touchpads for increased sales

  • Jones Day
  • -
  • Germany
  • -
  • December 6 2012

Medical device manufacturers whose products more closely resemble consumer goods may be inclined to lose sight of German health care compliance legislation

Current Search

Suggested Facets

Author

Firm Name

Jurisdiction

Workarea

© Copyright 2006-2013 Globe Business Publishing Ltd | Cookies | Disclaimer | Privacy policy